Study: Medicare Coverage Of Novo Nordisk’s Semaglutide For CVD Could Reach $145 Billion Annually

By Maaisha Osman / September 4, 2024 at 4:56 PM

As Congress debates expanding Medicare coverage to include a new class of weight-loss drugs, a recent study reveals that CMS’ decision to already cover Novo Nordisk's blockbuster drug Wegovy under Medicare Part D for cardiovascular risk reduction in specific patients could cost the U.S. government up to $145 billion annually.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.